Eugenia G. Bertoldo
Verona, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis.
Journal: Frontiers in immunology
Published: December 15, 2024
Expanding the VEXAS diagnostic workup: the role of peripheral blood cytological analysis.
Journal: Frontiers in immunology
Published: July 18, 2024
EULAR recommendations for the treatment of systemic sclerosis: 2023 update.
Journal: Annals of the rheumatic diseases
Published: July 16, 2024
Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis.
Journal: Annals of the rheumatic diseases
Published: July 16, 2024
The role of 18FDG-PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature.
Journal: Internal and emergency medicine
Published: May 02, 2024
Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study.
Journal: Clinical rheumatology
Published: April 26, 2024
The potential pathogenic role of gut microbiota in rheumatic diseases: a human-centred narrative review.
Journal: Internal and emergency medicine
Published: August 24, 2023
JAK inhibitors for the treatment of VEXAS syndrome.
Journal: Experimental biology and medicine (Maywood, N.J.)
Published: May 27, 2023
Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database.
Journal: Bone
Published: February 14, 2023
Association between acute exposure to environmental air pollution and fragility hip fractures.
Journal: Bone
Published: July 15, 2022
Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis.
Journal: Scandinavian journal of rheumatology
Published: June 20, 2022
Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
Journal: Therapeutic advances in musculoskeletal disease
Published: May 09, 2022
Last Updated: 09/26/2026